Real-life Study of How to Intensify Treatment With Xolair (OMALIZUMAB) in Chronic Spontaneous Urticaria (INTENXO)

University Hospital, Lille

Status: Enrolling

Conditions: Spontaneous Urticaria, Chronic

Study type: Observational

Funder types: Other

Identifiers

NCT04583475

2019_19

2019-A02662-55 (Other Identifier)

Details and patient eligibility

About

This is an observational study whose main objective is to estimate the frequency of patients benefiting from an intensification of AOM treatment at 3 months.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient having expressed non-opposition
• Affiliation to a social protection scheme (beneficiary or entitled person)
• Decision by the investigator to initiate, independently of the study, an AOM treatment for Spontaneous Chronic Urticaria that may or may not be associated with an inducible component.

Exclusion criteria

• Patients < 18 years of age
• Patient who had previously received AOM treatment prior to the inclusion visit
• Patients under guardianship or curatorship
• Pregnant or breastfeeding woman